News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Ultragenyx Pharmaceutical Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Business
Does Genentech Have a New Mega-Blockbuster?
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
November 27, 2017
·
1 min read
·
Karl Thiel
Policy
6 Biotechs Facing Make-or-Break FDA PDUFA Catalysts in November
Here’s a closer look at six drugs facing FDA decisions in November.
October 31, 2017
·
2 min read
·
Mark Terry
Deals
Bay Area’s Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics
September 18, 2017
·
3 min read
Drug Development
Bay Area’s Ultragenyx Tanks as Seizure Drug Flunks Phase II Test
March 23, 2017
·
3 min read
Bio NC
10 Biotech Stocks that Could Blow Up in Q3
July 6, 2016
·
3 min read
Biotech Bay
Nine Bay Area Biotechs Vie to be the “Next Genentech”
May 24, 2016
·
4 min read
Business
Arcturus Therapeutics Stands to Collect Up to $1.66 Billion from Rare Disease Pact with Ultragenyx
October 29, 2015
·
3 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 20, 2023
October 20, 2023
·
1 min read
Biotech Bay
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - October 19, 2023
October 18, 2023
·
4 min read
Biotech Bay
Ultragenyx Announces Proposed Public Offering of Common Stock - October 17, 2023
October 17, 2023
·
3 min read
Biotech Bay
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
October 16, 2023
·
7 min read
Drug Development
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
October 14, 2023
·
14 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 12, 2023
October 12, 2023
·
2 min read
Biotech Bay
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
October 9, 2023
·
7 min read
Biotech Bay
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
October 5, 2023
·
3 min read
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
September 25, 2023
·
6 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 20, 2023
September 20, 2023
·
1 min read
